Presbia Announces New Management Appointments
February 13 2018 - 7:00PM
Business Wire
Presbia PLC (NASDAQ: LENS, or the “Company”), an ophthalmic
device company and leader in near-vision restoration, announced
that Casey Lind has been appointed as Chief Operating Officer
effective February 12, 2018. As Chief Operating Officer, Ms. Lind
is responsible for the Company’s manufacturing, engineering,
quality and IT departments. Ms. Lind brings over 30 years of
experience, including 29 years at Alcon where she was in senior
leadership positions across manufacturing, global supply chain, and
research & development. Ms. Lind has numerous issued patents
ranging from drug delivery and injection control of manufacturing
processes for phase transition drug formulations. Ms. Lind also has
an active role at both the national and local levels in Ophthalmic
World Leaders (OWL). Ms. Lind is a graduate of Iowa State
University, with a degree in Business, and received her MBA from
Webster University.
In addition, the Company announced that Dr. Magda Michna, PhD
will become Chief Clinical Officer, also effective February 12,
2018. Dr. Michna will increase her responsibility overseeing
clinical affairs to also include the Company’s medical affairs and
regulatory functions. Dr. Michna joined the Company in February
2017 as VP of Clinical Affairs, bringing more than 12 years of
experience in ophthalmic clinical research and development. Prior
to Presbia, Dr. Michna worked at Alcon, Johnson & Johnson
Vision, and in academic research at the McGill University School of
Ophthalmology.
“We have assembled a leading ophthalmic management team at
Presbia,” said Mark Yung, Chairman and CEO of Presbia. “I am
looking forward to working with Casey and Magda, given their
extensive ophthalmic experience, and the rest of the team to
advance the Flexivue Microlens™ as an FDA-approved optical lens
implant that is available to the global presbyopia market.”
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Information provided and statements contained
in this press release that are not purely historical are
forward-looking statements. These statements are typically preceded
by words such as “believes,” “expects,” “anticipates,” “intends,”
“will,” “may,” “should,” or similar expressions. Such
forward-looking statements only speak as of the date of this press
release and Presbia assumes no obligation to update the
information included in this press release. Statements made in this
press release that are forward-looking in nature may involve risks
and uncertainties, including, but not limited to, the factors
listed under “Risk Factors” in our annual report on Form 10-K for
the year ended December 31, 2016, quarterly reports on Form 10-Q,
and other reports that Presbia files with the SEC. Accordingly,
readers are cautioned that any such forward-looking statements are
not guarantees and are subject to certain risks, uncertainties and
assumptions that are difficult to predict.
Although Presbia believes that the expectations reflected
in such forward-looking statements are reasonable as of the date
made, expectations may prove to have been materially different from
the results expressed or implied by such forward-looking
statements. Unless otherwise required by
law, Presbia also disclaims any obligation to update its
view of any such risks or uncertainties or to announce publicly the
result of any revisions to the forward-looking statements made in
this press release.
About Presbia
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company
that has developed and is currently marketing the
presbyopia-correcting Presbia Flexivue Microlens™, a
miniature lens that is implanted in a corneal pocket created by a
femtosecond laser. The Presbia Flexivue Microlens™ has received a
CE mark for the European Economic Area, allowing the lens to be
marketed in over 30 countries across Europe. A staged
pivotal U.S. clinical trial for the Presbia Flexivue
Microlens™ commenced in 2014.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180213006700/en/
Presbia PLCRick Fogarty,
949-502-7036rick@presbia.comorMonica Yamada,
323-860-4903monica@presbia.com
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2024 to Jul 2024
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2023 to Jul 2024